PP405 and PTD-DBM: How Similar Are They, Really?
Published by AmpleLab Research
Both PP405 (suvomipic) and PTD-DBM were developed with the aim of reactivating dormant hair follicle stem cells, from completely different starting points. PP405 works by inhibiting the mitochondrial pyruvate carrier, shifting cell metabolism toward glycolysis. PTD-DBM works by disrupting a specific protein-protein interaction that suppresses Wnt/beta-catenin signalling. Different biology entirely, similar underlying goal.
Where they genuinely diverge is evidence stage and availability, and that gap is wide enough that it's worth being upfront about it before anything else: PP405 has human trial data behind it and is not available to buy anywhere; PTD-DBM has animal and in vitro data behind it and is available now, as a cosmetic. This article covers both mechanisms briefly, then focuses on that evidence and availability comparison honestly.
What Each Compound Actually Targets
PP405 inhibits the mitochondrial pyruvate carrier (MPC), forcing cells to rely more heavily on glycolysis rather than mitochondrial oxidative phosphorylation. In mouse and ex vivo human follicle models, that metabolic shift has been associated with reactivating dormant follicle bulge stem cells. Full detail in our article on PP405 and JXL069.
PTD-DBM competes with CXXC5, a negative feedback regulator, for a binding site on Dishevelled (Dvl), a scaffold protein central to Wnt/beta-catenin signalling. By blocking CXXC5 from suppressing the pathway, PTD-DBM disinhibits Wnt signalling the follicle already has the machinery to run. It doesn't add an external growth signal; it removes a specific brake on an existing one. Full detail in our article on what is PTD-DBM.
The Research Each Mechanism Is Actually Built On
The UCLA team behind PP405's underlying research (Christofk, Lowry, Jung) published this medicinal chemistry paper synthesising and evaluating a series of MPC inhibitor analogues, including JXL069, for their effect on hair follicle biology. This is the foundational chemistry connecting MPC inhibition to hair growth, and the paper that later independent analysis used to identify PP405's structural match with JXL069, covered in our article on PP405 and JXL069.
The foundational paper behind PTD-DBM's mechanism, though not about hair at all: the Choi laboratory first identified CXXC5 as a negative feedback regulator of Wnt/beta-catenin signalling in osteoblast (bone-forming cell) biology, establishing the CXXC5-Dvl interaction as a specific, addressable target years before its hair-specific application.
The paper that introduced PTD-DBM itself, moving the CXXC5-Dvl research from bone into wound healing. Tested in human dermal fibroblasts in vitro at 2 µM and 10 µM, PTD-DBM produced statistically significant effects on cell migration and beta-catenin levels. This is the first data specifically on PTD-DBM, as distinct from the broader CXXC5 target, and the first in human cells rather than mouse or osteoblast models.
PTD-DBM's primary hair-specific evidence. Topical application to C57BL/6N mice accelerated hair regrowth versus controls and promoted wound-induced follicle neogenesis, the formation of entirely new follicle units within healing tissue. The same paper confirmed CXXC5 upregulation in miniaturised follicles in human balding scalp tissue, the human biological evidence for relevance to AGA specifically, though not a human dosing trial.
Where Each Actually Stands, Evidence-Wise
This is the comparison that actually matters, and it's not close.
PP405 is genuinely further along by the measure that matters most, human trial data, even accounting for the fact that Phase 2a results are sponsor-reported topline figures rather than a completed peer-reviewed publication. PTD-DBM's evidence sits earlier in the pipeline: animal and in vitro data, plus confirmation that its molecular target is elevated in human balding scalp tissue, but no human dosing trial of any kind.
Neither compound has been tested against the other, or in combination. This comparison is drawn from two entirely separate research programmes; there's no head-to-head data of any kind.
The Availability Gap Runs the Opposite Direction
Despite having less human evidence behind it, PTD-DBM is something you can actually buy today, formulated as a cosmetic serum. PP405 is not available to anyone outside Pelage's clinical trial programme, and won't be for years even in the best case: Phase 3 trials and the full regulatory review process still have to happen before any approval, and there's currently no confirmed launch date. The grey-market version of the underlying molecule, sold as JXL069, carries its own separate risks we've covered elsewhere and wouldn't recommend.
That's the trade-off in plain terms: PP405 has more human evidence and isn't available; PTD-DBM is available now and has less human evidence. Neither fact cancels the other out, and we'd rather state both clearly than let either one imply more than it does.
Where This Leaves Someone Deciding
We're not going to claim PTD-DBM is "as good as" PP405, that's not a claim the evidence supports either way, given the two haven't been tested against each other and PP405's own human data is still topline and unpublished. What we can say honestly is that PTD-DBM represents a different, mechanistically distinct route to a similar biological goal, backed by a multi-year research programme from an academic lab, available now rather than pending years of further trials.
If PP405's Phase 3 results hold up and it eventually reaches approval, it will do so with a human clinical evidence base PTD-DBM doesn't currently have, and we'd say so plainly if that happens. In the meantime, PTD-DBM is a currently available cosmetic ingredient built on genuine, earlier-stage research, formulated as 0.01% PTD-DBM Hair and Scalp Serum, with concentration, INCI, and mechanism disclosed publicly rather than left for the buyer to work out.
Frequently Asked Questions
Is PTD-DBM a substitute for PP405?
Not in an evidence sense, no. PP405 has completed Phase 2a human trial data; PTD-DBM's evidence is animal and in vitro. They're mechanistically distinct compounds addressing a similar downstream goal through different pathways, not interchangeable versions of the same thing.
Can I use PTD-DBM while waiting for PP405 to become available?
That's a reasonable way to think about it, provided you're clear-eyed about PTD-DBM's own evidence stage rather than treating it as a proxy for PP405's results. It's a genuinely available option built on real, earlier-stage research, not a stand-in with equivalent backing.
Do PP405 and PTD-DBM work through the same pathway?
No. PP405 works through mitochondrial pyruvate carrier inhibition and metabolic reprogramming. PTD-DBM works through Wnt/beta-catenin pathway disinhibition via CXXC5 blockade. Both are proposed to converge on reactivating follicle stem cells, but via distinct upstream mechanisms, and there's no research testing whether combining approaches like these would be additive.
Why does PP405 have human data and PTD-DBM doesn't, if PTD-DBM's research is older?
Research age and clinical progress aren't the same thing. PTD-DBM's foundational research dates to 2015-2017, but as far as we're aware it hasn't been taken into a funded clinical trial programme. PP405 has that behind it, via Pelage Pharmaceuticals' $120 million Series B and dedicated drug development pipeline. Being an older discovery doesn't guarantee faster progress to human trials; that depends on funding and a company committed to the regulatory pathway.
Selected Research
This article is provided for educational purposes. PP405/suvomipic is an investigational drug not approved by any regulator and not available outside Pelage Pharmaceuticals' clinical trials. AmpleLab's PTD-DBM Hair and Scalp Serum is a cosmetic formulation and is not intended to diagnose, treat, cure, or prevent any condition. The research referenced for both compounds is pre-clinical or early-stage; no clinical hair regrowth claims are made for PTD-DBM.
AmpleLab.